Document Detail


Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy.
MedLine Citation:
PMID:  11238857     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have previously described two replication-competent adenovirus vectors, named KD1 and KD3, for potential use in cancer gene therapy. KD1 and KD3 have two small deletions in the E1A gene that restrict efficient replication of these vectors to human cancer cell lines. These vectors also have increased capacity to lyse cells and spread from cell to cell because they overexpress the adenovirus death protein, an adenovirus protein required for efficient cell lysis and release of adenovirus from the cell. We now describe a new vector, named KD1-SPB, which is the KD1 vector with the E4 promoter replaced by the promoter for surfactant protein B (SPB). SPB promoter activity is restricted in the adult to type II alveolar epithelial cells and bronchial epithelial cells. Because KD1-SPB has the E1A mutations, it should replicate within and destroy only alveolar and bronchial cancer cells. We show that KD1-SPB replicates, lyses cells, and spreads from cell to cell as well as does KD1 in H441 cells, a human cancer cell line where the SPB promoter is active. KD1-SPB replicates, lyses cells, and spreads only poorly in Hep3B liver cancer cells. Replication was determined by expression of the E4ORF3 protein, viral DNA accumulation, fiber synthesis, and virus yield. Cell lysis and vector spread were measured by lactate dehydrogenase release and a "vector spread" assay. In addition to Hep3B cells, KD1-SPB also did not express E4ORF3 in HT29.14S (colon), HeLa (cervix), KB (nasopharynx), or LNCaP (prostate) cancer cell lines, in which the SPB promoter is not expected to be active. Following injection into H441 or Hep3B tumors growing in nude mice, KD1-SPB caused a three- to fourfold suppression of growth of H441 tumors, similar to that seen with KD1. KD1-SPB had only a minimal effect on the growth of Hep3B tumors, whereas KD1 again caused a three- to fourfold suppression. These results establish that the adenovirus E4 promoter can be replaced by a tissue-specific promoter in a replication-competent vector. The vector has three engineered safety features: the tissue-specific promoter, the mutations in E1A that preclude efficient replication in nondividing cells, and a deletion of the E3 genes which shield the virus from attack by the immune system. KD1-SPB may have use in treating human lung cancers in which the SPB promoter is active.
Authors:
K Doronin; M Kuppuswamy; K Toth; A E Tollefson; P Krajcsi; V Krougliak; W S Wold
Related Documents :
14657387 - Viral protein u counteracts a human host cell restriction that inhibits hiv-1 particle ...
10426207 - Growth behavior of bovine herpesvirus-1 in permissive and semi-permissive cells.
12069767 - Early interaction of canine calicivirus with cells is the major determinant for its cel...
110697 - Antigenic differences between extracts of actively replicating and synchronized resting...
11121377 - Chromaffin-adrenocortical cell interactions: effects of chromaffin cell activation in a...
4365757 - Immunofluorescence evidence for the distribution of cyclic amp in cells and cell masses...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of virology     Volume:  75     ISSN:  0022-538X     ISO Abbreviation:  J. Virol.     Publication Date:  2001 Apr 
Date Detail:
Created Date:  2001-03-12     Completed Date:  2001-04-05     Revised Date:  2013-04-18    
Medline Journal Info:
Nlm Unique ID:  0113724     Medline TA:  J Virol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3314-24     Citation Subset:  IM    
Affiliation:
Department of Molecular Microbiology and Immunology, St. Louis University School of Medicine, St. Louis, Missouri, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenovirus E1A Proteins / genetics
Adenovirus E4 Proteins / biosynthesis
Adenoviruses, Human / genetics*,  physiology
Animals
DNA Replication
Genetic Therapy*
Genetic Vectors*
Humans
Mice
Neoplasms / therapy*
Organ Specificity
Promoter Regions, Genetic
Tumor Cells, Cultured
Virus Replication*
Grant Support
ID/Acronym/Agency:
CA71704/CA/NCI NIH HHS; CA81829/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Adenovirus E1A Proteins; 0/Adenovirus E4 Proteins
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Human immunodeficiency virus type 1 central DNA flap: dynamic terminal product of plus-strand displa...
Next Document:  Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and I...